A meta-analysis of CXCL12 expression for cancer prognosis

摘要: CXCL12 (SDF1) is reported to promote cancer progression in several preclinical models and this corroborated by the analysis of human tissue specimens. However, relationship between expression survival has not been systematically assessed. We conducted a systematic review meta-analysis studies that evaluated association survival. Thirty-eight inclusive 5807 patients were included overall, recurrence-free or cancer-specific survival, majority which retrospective. The pooled hazard ratios (HRs) for overall with high 1.39 (95% CI: 1.17–1.65, P=0.0002) 1.12 0.82–1.53, P=0.48) respectively, but significant heterogeneity studies. On subgroup type, was associated reduced oesophagogastric (HR 2.08; 95% 1.31–3.33, P=0.002), pancreatic 1.54; 1.21–1.97, P=0.0005) lung 1.37; 1.08–1.75, P=0.01), whereas breast conferred an advantage 0.5; 0.38–0.66, P<0.00001). Determination potential be use as biomarker adds prognostic information various types. Prospective prospective–retrospective analyses clearly defined cohorts are now required advance our understanding outcome.